Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Seminars in Oncology|August 27, 2003
Rituximab in B-cell chronic lymphocytic leukemiaThomas S Lin, Margaret S Lucas, John C Byrd
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2007
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteriaKristie A Blum, Donn Young, Sarah Broering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemiaYvette L Kasamon, Ian W Flinn, Michael R Grever, et al.
Blood|June 26, 2004
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemiaThomas S Lin, Ian W Flinn, Rama Modali, et al.
Leukemia & Lymphoma|October 29, 2009
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemiaThomas S Lin, Louie Naumovski, Philip S Lecane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Leukemia & Lymphoma|October 29, 2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemiaThomas S Lin, Wendy Stock, Huiping Xu, et al.
Leukemia & Lymphoma|February 12, 2015
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphomaFarrukh T Awan, Joseph M Flynn, Jeffrey A Jones, et al.
Blood Advances|October 8, 2020
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonistsKristin L Koenig, Ying Huang, Emily K Dotson, et al.
Pageof 1